Butterfly Medical Hires Olympus Exec as New CEO

Butterfly Medical, an early-stage company focused on alleviating suffering in BPH (benign prostatic hyperplasia) patients, has welcomed Patrick MacCarthy as its new CEO.
 
MacCarthy has over 20 years of healthcare leadership experience, leading teams to commercialize multiple devices in gastroenterology, pulmonology, thoracic surgery, gynecology, and urology. He was most recently head of Olympus America’s urology and gynecology business unit.
 
“We are thrilled to welcome Pat as our new CEO for Butterfly Medical,” said Greg Parekh, Butterfly Medical’s chairman, managing partner of New Rhein Healthcare Investors, and former head of M&A at Novartis. “With deep cross-functional expertise in large and start-up healthcare companies, Pat is well positioned to lead Butterfly Medical to clinical and commercial success. We are committed to helping the more than 90 million men globally who suffer from BPH symptoms, one of the fastest growing and most prevalent disease-states.”
 
“The Butterfly Medical team has created an innovative, anatomically-shaped device designed to treat urinary obstruction from BPH, without the significant side-effects seen in drugs or surgical treatments,” added MacCarthy. “I chose Butterfly Medical because I saw significant value in its unique technology and because of the strength of the management team, clinicians, partners and investors. Having obtained regulatory approval and CE mark in Europe, we are focused on completing our U.S. pivotal clinical study and achieving FDA clearance.”
 
The Butterfly device has been successfully used in more than 250 patients in the U.S., Europe, and Israel. It has over five years of outcomes data.
 
The device is currently being assessed in an investigational device exemption (IDE) trial in the U.S.